Biomerica's H pylori test:
This article was originally published in Clinica
Executive Summary
Biomerica has received CE mark approval for the Fortel HP Ulcer Test, its home diagnostic for Helicobacter pylori, a bacterium responsible for over 85% of gastric ulcers. The firm, based in Newport Beach, California, said that it was already in discussions with several significant distributors for the 15-minute one-step blood test. H pylori infection is widespread, affecting over one billion people worldwide. Nearly all duodenal ulcer patients and over 80% of stomach ulcer patients are infected with the bacterium, and it is estimated that the worldwide anti-ulcer market is worth over $9.5bn.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.